Back to Cell Types

NCI-H1092Homo sapiens (Human)Cancer cell line

Also known as: NCIH1092, H-1092, H1092

🤖 AI SummaryBased on 12 publications

Quick Overview

Human small cell lung cancer cell line with known genetic alterations.

Detailed Summary

The NCI-H1092 cell line is a human small cell lung cancer (SCLC) cell line derived from a patient with lung cancer. It is widely used in cancer research to study the molecular mechanisms of SCLC and to evaluate potential therapeutic targets. This cell line has been characterized for its genetic and molecular features, including mutations in key oncogenes and tumor suppressor genes. Research on NCI-H1092 has contributed to understanding the role of specific genetic alterations in cancer progression and drug resistance. It is also utilized in studies related to the identification of novel biomarkers and the development of targeted therapies.

Research Applications

Molecular mechanisms of SCLCTherapeutic target identificationBiomarker discoveryDrug resistance studies

Key Characteristics

Genetic alterations in oncogenes and tumor suppressor genesUsed in drug sensitivity and resistance studiesCharacterized for molecular features

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1454
Species	Homo sapiens (Human)
Tissue Source	Bone marrow[UBERON:UBERON_0002371]

Donor Information

Additional Information	Established from a 120 packs per year smoker (ATCC=CRL-5855)
Age	67
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Small cell lung cancer
Lineage	Lung
Subtype	Small Cell Lung Cancer
OncoTree Code	SCLC

DepMap Information

Source Type	ATCC
Source ID	ACH-000514_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	c.673-2A>C (IVS6-2A>C)	Heterozygous	Splice acceptor mutation	Unknown, Unknown
MutationSimple	JUN	p.Glu282Ter (c.844G>T)	Heterozygous	-	Unknown, Unknown
MutationSimple	CTNNB1	p.Asp6Gly (c.17A>G)	Homozygous	-	Unknown, Unknown, Unknown, PubMed=11464291

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

11

D13S317

11,14

D16S539

11,12

D18S51

14

D19S433

14,16

D21S11

29,33.2

D2S1338

18,20

D3S1358

17

D5S818

12

D7S820

10,12

D8S1179

13,14

FGA

21,24

Penta D

12,13

Penta E

13

TH01

7,9.3

TPOX

8,11

vWA

15,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.

Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.

Oncogene 20:4249-4257(2001).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Ihde D.C., Gazdar A.F.

J. Cell. Biochem. Suppl. 24:210-217(1996).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Insulin-like growth factor expression in human cancer cell lines.";

Grimley C., Battey J., Mulshine J.L., Cuttitta F.

J. Biol. Chem. 271:11477-11483(1996).

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Linnoila R.I.

Oncogene 7:743-749(1992).

Neuromedin B is present in lung cancer cell lines.";

Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.

Cancer Res. 52:2732s-2736s(1992).

High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.

Gazdar A.F., Minna J.D.

Oncogene 7:339-346(1992).